Literature DB >> 19228722

Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry.

Yoshinobu Komai1, Mutsunori Fujiwara, Yasuhisa Fujii, Hiroyuki Mukai, Junji Yonese, Satoru Kawakami, Shinya Yamamoto, Toshiro Migita, Yuichi Ishikawa, Morito Kurata, Takuro Nakamura, Iwao Fukui.   

Abstract

PURPOSE: To determine the incidence of Xp11 translocation renal cell carcinoma (RCC) in adult patients using cytogenetics and immunohistochemstry. EXPERIMENTAL
DESIGN: Cytogenetic studies were prospectively done using tumor samples from 443 consecutive adult Japanese patients (ages 15-89 years) who underwent nephrectomy for RCC. TFE3 immunohistochemistry was done for cases in which cytogenetic results were not obtained. Clinicopathologic characteristics of Xp11 translocation RCC were examined.
RESULTS: Mitotic cells suitable for cytogenetic analysis were obtained in 244 tumor samples (55%); among these, we identified 4 cases (1.6%) of Xp11 translocation RCC. TFE3 immunohistochemistry identified 3 positive cases (1.5%) among the remaining 199 cases. The median age of the 7 patients was 41 years (range, 15-59 years), and 15% of RCC patients (4 of 26) who were younger than ages 45 years had this type of RCC. Of the four Xp11 translocation RCC patients whose karyotypes were determined, two had an ASPL-TFE3 gene fusion. Of these 2, 1 had pulmonary metastasis at presentation, and the other developed liver metastasis 12 months after nephrectomy and died of the disease. The remaining two patients had PRCC-TFE3 and PSF-TFE3 gene fusions, respectively. Both had nodal involvement but remained disease free for 3 and 5 years, respectively, after surgical resection of lymph node metastases. Of the 3 immunohistochemically diagnosed patients, 1 had nodal metastases at presentation and died 9 months after surgery.
CONCLUSIONS: This is the first report to determine the incidence of Xp11 translocation RCC in adult patients. We found that this disease is relatively common in young adults.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19228722     DOI: 10.1158/1078-0432.CCR-08-1183

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  63 in total

1.  Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers.

Authors:  Pedram Argani; Jessica Hicks; Angelo M De Marzo; Roula Albadine; Peter B Illei; Marc Ladanyi; Victor E Reuter; George J Netto
Journal:  Am J Surg Pathol       Date:  2010-09       Impact factor: 6.394

2.  Translocation renal cell carcinomas in adults: a single-institution experience.

Authors:  Minghao Zhong; Patricia De Angelo; Lisa Osborne; Alberto E Paniz-Mondolfi; Matthew Geller; Youfeng Yang; W Marston Linehan; Maria J Merino; Carlos Cordon-Cardo; Dongming Cai
Journal:  Am J Surg Pathol       Date:  2012-05       Impact factor: 6.394

3.  Xp11.2 translocation renal cell carcinoma with PSF-TFE3 rearrangement.

Authors:  Minghao Zhong; Paul Weisman; Bing Zhu; Maria Brassesco; Youfeng Yang; W Marston Linehan; Maria J Merino; David Zhang; Stephen Rohan; Dongming Cai; Ximing Yang
Journal:  Diagn Mol Pathol       Date:  2013-06

4.  Laparoscopic radiofrequency ablation-assisted enucleation of Xp11.2 translocation renal cell carcinoma: A case report.

Authors:  Linfeng Xu; Rong Yang; Wei Wang; Yifen Zhang; Weidong Gan
Journal:  Oncol Lett       Date:  2014-06-18       Impact factor: 2.967

5.  Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma.

Authors:  Nur P Damayanti; Justin A Budka; Heba W Z Khella; Mary W Ferris; Sheng Yu Ku; Eric Kauffman; Anthony C Wood; Khunsha Ahmed; Venkata Nithinsai Chintala; Remi Adelaiye-Ogala; May Elbanna; Ashley Orillion; Sreenivasulu Chintala; Chinghai Kao; W Marston Linehan; George M Yousef; Peter C Hollenhorst; Roberto Pili
Journal:  Clin Cancer Res       Date:  2018-07-30       Impact factor: 12.531

6.  Xp11.2 translocation renal cell carcinoma with TFE3 gene fusion: A case report.

Authors:  Xiang Pan; Jing Quan; Liwen Zhao; Wenhua Li; Benlin Wei; Shangqi Yang; Yongqing Lai
Journal:  Mol Clin Oncol       Date:  2017-11-13

Review 7.  Choosing The Right Animal Model for Renal Cancer Research.

Authors:  Paweł Sobczuk; Anna Brodziak; Mohammed Imran Khan; Stuti Chhabra; Michał Fiedorowicz; Marlena Wełniak-Kamińska; Kamil Synoradzki; Ewa Bartnik; Agnieszka Cudnoch-Jędrzejewska; Anna M Czarnecka
Journal:  Transl Oncol       Date:  2020-02-22       Impact factor: 4.243

Review 8.  Recent developments in the treatment of renal cell carcinoma.

Authors:  Janice P Dutcher
Journal:  Ther Adv Urol       Date:  2013-12

Review 9.  [The translocation carcinoma: A pediatric renal tumor also in adults].

Authors:  E Bruder; H Moch
Journal:  Pathologe       Date:  2016-03       Impact factor: 1.011

10.  TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.

Authors:  Pedram Argani; Minghao Zhong; Victor E Reuter; John T Fallon; Jonathan I Epstein; George J Netto; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2016-06       Impact factor: 6.394

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.